Heart Failure And Cardiomyopathies

Historical Context & Motivation

The concept of heart failure has evolved dramatically from its earliest descriptions as simple "dropsy" — a clinical state of generalized edema — to the sophisticated neurohormonal model we apply today. Ancient physicians, including Hippocrates, recognized fluid accumulation in the lungs and extremities but lacked a mechanistic understanding of the heart's pump function. It was not until William Harvey's landmark description of the circulation in 1628 that the concept of the heart as a central pump became established, providing the intellectual foundation for all subsequent work on cardiac failure. Over the ensuing centuries, clinicians and scientists progressively elucidated the hemodynamic, structural, and molecular underpinnings of heart failure, transforming it from a death sentence to a chronic condition manageable with evidence-based therapies.

Today, the central clinical question in heart failure is not merely whether the heart is failing, but why it is failing, how the failure manifests hemodynamically, and which evidence-based interventions can modulate the underlying neurohormonal cascade. A sophisticated understanding of cardiomyopathy subtypes — dilated, hypertrophic, restrictive, and arrhythmogenic — is essential because the etiology determines prognosis, risk stratification, and therapeutic strategy. This lesson integrates these concepts for Step 2 clinical reasoning.

Core Principles & Definitions

Heart failure is defined as a clinical syndrome in which the heart cannot maintain adequate cardiac output to meet the metabolic demands of the body, or can do so only at the expense of elevated filling pressures. This definition encompasses both systolic dysfunction (reduced contractility) and diastolic dysfunction (impaired relaxation and filling). The modern classification scheme stratifies patients by left ventricular ejection fraction (LVEF) into HFrEF (≤40%), HFmrEF (41–49%), and HFpEF (≥50%), because these categories predict different pathophysiology, response to therapy, and prognosis.

Visual Explanation — Heart Failure Pathophysiology

The diagram above illustrates the core pathophysiologic feedback loop that drives heart failure progression. When cardiac output falls, arterial baroreceptors detect the decrease in perfusion pressure and signal the brainstem to augment sympathetic outflow. Simultaneously, reduced renal perfusion stimulates renin release from the juxtaglomerular apparatus, activating the angiotensin–aldosterone axis. Angiotensin II is a potent vasoconstrictor that increases afterload, while aldosterone promotes sodium and water retention, expanding intravascular volume and increasing preload. Although these mechanisms transiently support blood pressure and organ perfusion, chronic activation accelerates myocardial fibrosis, cardiomyocyte apoptosis, and adverse ventricular remodeling. This understanding explains why the four pillars of HFrEF therapy — ACE inhibitors/ARBs/ARNI, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors — all target components of this neurohormonal cascade.

Hemodynamic Framework & Key Equations

While heart failure is fundamentally a clinical diagnosis, understanding the hemodynamic relationships that govern cardiac performance is critical for interpreting invasive monitoring data (e.g., Swan-Ganz catheterization) and predicting the effects of pharmacologic interventions. The key parameters include cardiac output, stroke volume, preload, afterload, and contractility, all of which are interconnected through the Frank-Starling relationship and the determinants of ventricular performance.

The Frank-Starling mechanism describes how increased venous return (preload) stretches cardiomyocytes, enhancing actin-myosin overlap and augmenting stroke volume — up to a point. In the failing heart, the Starling curve is shifted downward and flattened: at any given preload, the failing ventricle generates less stroke volume than a normal heart. Furthermore, excessive preload in a failing ventricle leads to pulmonary or systemic congestion without meaningful improvement in output. This concept underpins the use of diuretics to relieve congestion (moving the patient leftward on the curve) and positive inotropes to shift the curve upward in acute decompensation.

Cardiomyopathy Classification & Differentiation

Cardiomyopathies are classified by morphologic and functional criteria into four major subtypes. Each presents with a distinct echocardiographic pattern, hemodynamic profile, and clinical trajectory. Understanding these distinctions is essential for Step 2 because management varies significantly across types — for example, positive inotropes that benefit dilated cardiomyopathy are contraindicated in hypertrophic obstructive cardiomyopathy, where they worsen the dynamic outflow tract obstruction.

Worked Clinical Example — HFrEF Management

A 58-year-old male with a history of anterior STEMI two years ago presents with progressive dyspnea on exertion (NYHA Class III), orthopnea, and bilateral lower extremity edema. Exam reveals an elevated JVP, bibasilar crackles, and an S3 gallop. Echocardiography shows an LVEF of 25% with global hypokinesis. BNP is 980 pg/mL. His current medications include aspirin, atorvastatin, and lisinopril 5 mg daily. Creatinine is 1.2 mg/dL and potassium is 4.1 mEq/L. How should his heart failure regimen be optimized?

Pharmacologic Agents — Comparison & Contraindications

The pharmacologic management of heart failure varies substantially depending on the EF category and the underlying cardiomyopathy subtype. For HFrEF, there is strong randomized controlled trial evidence supporting each of the four pillars. For HFpEF, the evidence base has historically been more limited, though SGLT2 inhibitors have recently demonstrated benefit across the EF spectrum. Understanding which agents are beneficial, which are neutral, and which are harmful in specific clinical contexts is a high-yield testing point for Step 2.

Advanced Heart Failure & Special Populations

Despite optimal medical therapy, a subset of patients progress to advanced (Stage D) heart failure, characterized by refractory symptoms at rest, recurrent hospitalizations, and need for specialized interventions. The ACC/AHA staging system (A through D) is distinct from the NYHA functional classification: while NYHA class fluctuates with treatment, ACC/AHA stage only progresses forward. Stage D patients require consideration of mechanical circulatory support, cardiac transplantation, or palliative care.

Looking forward, the field of heart failure is rapidly evolving with gene therapy approaches for inherited cardiomyopathies, novel neurohormonal targets beyond the traditional RAAS axis (e.g., soluble guanylate cyclase stimulators like vericiguat for worsening HF), and growing use of wearable hemodynamic monitors (CardioMEMS) for remote management of filling pressures. A solid foundation in the pathophysiology and pharmacology presented in this lesson prepares you to integrate these advances as they enter clinical practice and appear on licensing examinations.

Practice Problems

Heart Failure & Cardiomyopathies — Key Concepts Review